Cargando…

AB087. The biotherapy for bladder cancer

The high frequency of recurrence and poor survival rate of bladder cancer demand exploration of novel strategies. Biotherapy strategies include immunotherapy, gene therapy, inducing cell apoptosis, and so on. Precious studies indicated that BCG could effectively prevent tumor recurrence, and signifi...

Descripción completa

Detalles Bibliográficos
Autor principal: Wang, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708678/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s087
_version_ 1782409520578822144
author Wang, Zhiping
author_facet Wang, Zhiping
author_sort Wang, Zhiping
collection PubMed
description The high frequency of recurrence and poor survival rate of bladder cancer demand exploration of novel strategies. Biotherapy strategies include immunotherapy, gene therapy, inducing cell apoptosis, and so on. Precious studies indicated that BCG could effectively prevent tumor recurrence, and significantly reduce tumor progression. Our studies showed that BCG combined with epirubicin could more effectively inhibit tumor recurrence and progression. But BCG also has its own side effects. Studies showed that Wan Te Puan induce tumor cell apoptosis by inhibit EGFR signaling pathway, and induce the conversion of macrophage and dendritic cells activation through improving immune microenvironment. We demonstrated that modified DC by cytokines has better antitumor effect. Promisingly, our group constructed a bladder cancer-specific adenovirus carrying E1A-androgen receptor (AR) under the control of UPII promoter and prostate stem cell antigen enhancer (PSCAE), designated as Ad/PSCAE/UPII/E1A-AR, and investigated its antitumor effects in vitro and in vivo. We demonstrated that Ad/PSCAE/UPII/E1A-AR could be selectively replicated in bladder tumor cell lines (5637, BIU87, EJ and T24) when compared with control adenovirus Ad/PSCAE/UPII/Luc. In addition, we demonstrated that intratumoral injection of Ad/PSCAE/UPII/E1A-AR into established subcutaneous human EJ tumors in nude mice could significantly regress the growth of tumor and markedly prolong survival for tumor-bearing mice; on the other hand, saline-treated tumors continued to grow rapidly. Importantly, there is no evidence of cytotoxicity for normal human bladder cell line SVHUC-1 and hepatoma cell line SMMC7721. Our study also showed that radiotherapy and chemotherapy synergistically enhanced the antitumor effect of oncolytic adenovirus. We found that recombinant adenovirus Ad/PSCAE/UPII/E1A-AR appear safe with 5×10(7) pfu and 5×10(8) pfu intratumorally injection in mice, without any discernable effects on general health and behavior. Furthermore, our findings provide a promising therapeutic modality for the treatment of bladder cancer.
format Online
Article
Text
id pubmed-4708678
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-47086782016-01-26 AB087. The biotherapy for bladder cancer Wang, Zhiping Transl Androl Urol Podium Lecture The high frequency of recurrence and poor survival rate of bladder cancer demand exploration of novel strategies. Biotherapy strategies include immunotherapy, gene therapy, inducing cell apoptosis, and so on. Precious studies indicated that BCG could effectively prevent tumor recurrence, and significantly reduce tumor progression. Our studies showed that BCG combined with epirubicin could more effectively inhibit tumor recurrence and progression. But BCG also has its own side effects. Studies showed that Wan Te Puan induce tumor cell apoptosis by inhibit EGFR signaling pathway, and induce the conversion of macrophage and dendritic cells activation through improving immune microenvironment. We demonstrated that modified DC by cytokines has better antitumor effect. Promisingly, our group constructed a bladder cancer-specific adenovirus carrying E1A-androgen receptor (AR) under the control of UPII promoter and prostate stem cell antigen enhancer (PSCAE), designated as Ad/PSCAE/UPII/E1A-AR, and investigated its antitumor effects in vitro and in vivo. We demonstrated that Ad/PSCAE/UPII/E1A-AR could be selectively replicated in bladder tumor cell lines (5637, BIU87, EJ and T24) when compared with control adenovirus Ad/PSCAE/UPII/Luc. In addition, we demonstrated that intratumoral injection of Ad/PSCAE/UPII/E1A-AR into established subcutaneous human EJ tumors in nude mice could significantly regress the growth of tumor and markedly prolong survival for tumor-bearing mice; on the other hand, saline-treated tumors continued to grow rapidly. Importantly, there is no evidence of cytotoxicity for normal human bladder cell line SVHUC-1 and hepatoma cell line SMMC7721. Our study also showed that radiotherapy and chemotherapy synergistically enhanced the antitumor effect of oncolytic adenovirus. We found that recombinant adenovirus Ad/PSCAE/UPII/E1A-AR appear safe with 5×10(7) pfu and 5×10(8) pfu intratumorally injection in mice, without any discernable effects on general health and behavior. Furthermore, our findings provide a promising therapeutic modality for the treatment of bladder cancer. AME Publishing Company 2015-08 /pmc/articles/PMC4708678/ http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s087 Text en 2015 Translational Andrology and Urology. All rights reserved.
spellingShingle Podium Lecture
Wang, Zhiping
AB087. The biotherapy for bladder cancer
title AB087. The biotherapy for bladder cancer
title_full AB087. The biotherapy for bladder cancer
title_fullStr AB087. The biotherapy for bladder cancer
title_full_unstemmed AB087. The biotherapy for bladder cancer
title_short AB087. The biotherapy for bladder cancer
title_sort ab087. the biotherapy for bladder cancer
topic Podium Lecture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708678/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s087
work_keys_str_mv AT wangzhiping ab087thebiotherapyforbladdercancer